Stonepine Capital Management LLC Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN)

Stonepine Capital Management LLC purchased a new position in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 132,870 shares of the company's stock, valued at approximately $417,000. Stonepine Capital Management LLC owned approximately 0.13% of Acelyrin at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SLRN. Dimensional Fund Advisors LP bought a new stake in Acelyrin in the 4th quarter valued at $371,000. Wellington Management Group LLP bought a new position in Acelyrin in the fourth quarter valued at about $567,000. Franklin Resources Inc. lifted its holdings in shares of Acelyrin by 36.9% during the third quarter. Franklin Resources Inc. now owns 128,591 shares of the company's stock worth $634,000 after purchasing an additional 34,642 shares during the period. Barclays PLC boosted its holdings in Acelyrin by 208.8% in the third quarter. Barclays PLC now owns 96,408 shares of the company's stock valued at $475,000 after acquiring an additional 65,188 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in shares of Acelyrin by 21.9% in the 4th quarter. Wells Fargo & Company MN now owns 52,014 shares of the company's stock worth $163,000 after acquiring an additional 9,332 shares in the last quarter. 87.31% of the stock is owned by institutional investors.

Insider Transactions at Acelyrin

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares of the company's stock, valued at approximately $1,840,603.22. The trade was a 2.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 13.60% of the company's stock.

Acelyrin Stock Performance

NASDAQ SLRN remained flat at $2.27 during mid-day trading on Friday. The company has a market cap of $229.17 million, a PE ratio of -0.92 and a beta of 1.07. Acelyrin, Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $7.25. The business has a 50 day simple moving average of $2.37 and a two-hundred day simple moving average of $2.90.

Acelyrin (NASDAQ:SLRN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.40. Sell-side analysts predict that Acelyrin, Inc. will post -2.53 earnings per share for the current fiscal year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.